Show Summary Details
Page of

Hormone replacement therapy (HRT) and selective oestrogen receptor modulators (SERMs) 

Hormone replacement therapy (HRT) and selective oestrogen receptor modulators (SERMs)
Chapter:
Hormone replacement therapy (HRT) and selective oestrogen receptor modulators (SERMs)
Author(s):

Jonathan H. Tobias

and Gavin Clunie

DOI:
10.1093/med/9780198713340.003.0008
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 08 April 2020

Hormone replacement therapy (HRT) and selective oestrogen receptor modulators (SERMs) exert beneficial effects on the skeleton in oestrogen-deficient states, resulting in a significant reduction in fracture risk in post-menopausal women.

The use of HRT and SERMs is limited by a small, but significant, increased risk of other adverse health outcomes.

HRT can be considered as the first-choice therapy for skeletal protection in girls with early-onset anorexia nervosa.

SERMs, such as raloxifene, may be justifiable in post-menopausal women at risk of osteoporosis with an increased risk of breast cancer.

Prolonged treatment with HRT and SERMs is probably best avoided, owing to uncertainties over their effects on the overall burden of disease.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.